The influence of neuroactive steroid lipophilicity on GABAA receptor modulation: evidence for a low-affinity interaction.
Anesthetic steroids with actions at gamma-aminobutyric acid type A receptors (GABA(A)Rs) may access transmembrane domain binding site(s) directly from the plasma cell membrane. Accordingly, the effective concentration in lipid phase and the ability of the steroid to meet pharmacophore requirements for activity will both contribute to observed steady-state potency. Furthermore, onset and offset of receptor effects may be rate limited by lipid partitioning. Here we show that several GABA-active steroids, including naturally occurring neurosteroids, of different lipophilicity differ in kinetics and potency at GABA(A)Rs. The hydrophobicity ranking predicted relative potency of GABA(A)R potentiation and predicted current offset kinetics. Kinetic offset differences among steroids were largely eliminated by gamma-cyclodextrin, a scavenger of unbound steroid, suggesting that affinity differences among the analogues are dwarfed by the contributions of nonspecific accumulation. A 7-nitrobenz-2-oxa-1,3-diazole (NBD)-tagged fluorescent analogue of the low-lipophilicity alphaxalone (C17-NBD-alphaxalone) exhibited faster nonspecific accumulation and departitioning than those of a fluorescent analogue of the high-lipophilicity (3alpha,5alpha)-3-hydroxypregnan-20-one (C17-NBD-3alpha5alphaA). These differences were paralleled by differences in potentiation of GABA(A)R function. The enantiomer of C17-NBD-3alpha5alphaA, which does not satisfy pharmacophore requirements for steroid potentiation, exhibited identical fluorescence kinetics and distribution to C17-NBD-3alpha5alphaA, but was inactive at GABA(A)Rs. Simple simulations supported our major findings, which suggest that neurosteroid binding affinity is low. Therefore both specific (e.g., fulfilling pharmacophore requirements) and nonspecific (e.g., lipid solubility) properties contribute to the potency and longevity of anesthetic steroid action.
Chisari
Mariangela
M
Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Eisenman
Lawrence N
LN
Krishnan
Kathiresan
K
Bandyopadhyaya
Achintya K
AK
Wang
Cunde
C
Taylor
Amanda
A
Benz
Ann
A
Covey
Douglas F
DF
Zorumski
Charles F
CF
Mennerick
Steven
S
D000818:Animals; D002462:Cell Membrane / Q000187:drug effects* / Q000502:physiology; D002478:Cells, Cultured; D003198:Computer Simulation; D005453:Fluorescence; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology; D057927:Hydrophobic and Hydrophilic Interactions; D007700:Kinetics; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D008959:Models, Neurological; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D010069:Oxadiazoles; D011280:Pregnanolone / Q000031:analogs & derivatives / Q000737:chemistry; D051381:Rats; D011963:Receptors, GABA-A / Q000378:metabolism*; D013256:Steroids / Q000737:chemistry / Q000494:pharmacology*; D014982:Xenopus laevis; D005680:gamma-Aminobutyric Acid / Q000378:metabolism; D047408:gamma-Cyclodextrins / Q000737:chemistry / Q000494:pharmacology
C526864:7-nitrobenz-2-oxa-1,3-diazole; D010069:Oxadiazoles; D011963:Receptors, GABA-A; D013256:Steroids; D047408:gamma-Cyclodextrins; D005680:gamma-Aminobutyric Acid; D011280:Pregnanolone; C023792:gamma-cyclodextrin